Eli Lilly on Friday crossed the $1 trillion market-cap threshold, becoming the first drugmaker to ever reach that milestone.

New GLP-1 weight-loss drugs may preserve muscle, protect skin, and reduce the risk of "Ozempic face." Experts explain what ...

NBC News' Anne Thompson joins "Here's the Scoop" co-host Yasmin Vossoughian to talk about why some people are microdosing GLP ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Absent tools such as rebate reform, transparent pricing or accelerated biosimilar substitution, true price competition will ...

U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss ...

Your gut changes on GLP-1s — but you don’t have to feel miserable. These 23 probiotics smooth digestion, calm bloating, and ...

Novo Nordisk A/S faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy. Learn more ...

“In general, we tend to see more weight loss with GLP-1-based medication treatment in patients who are female, those who do ...

Tirzepatide, semaglutide, and liraglutide lead to weight loss in adults with obesity and T1D over 1 year; the greatest weight ...

GLP-1 RAs are associated with a 62% reduction in 5-year mortality in colon cancer patients, especially those with high obesity. The study's findings remained significant after adjusting for ...

Purchases of food and beverage products high in carbohydrates and sugar are decreasing among GLP-1 users, who are “actively ...